KRYS / Krystal Biotech: A Buy For Growth Potential

Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news. more_horizontal

Krystal Biotech's FDA-approved gene therapy for DEB sets a medical milestone, opening new revenue streams. With a robust financial health, Krystal pre more_horizontal

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is o more_horizontal

Krystal Biotech recently reached an important milestone with the approval of its lead candidate Vyjuvek. Although this product represents a breakthrou more_horizontal

Last week, shares of the Pittsburgh-based genetic medicines developer surged more than 25% after the FDA approved its therapy for a rare skin disease more_horizontal

Krystal Biotech announced on Friday that Vyjuvek had been approved by the FDA to treat a rare skin disorder. The company said it plans to launch the g more_horizontal

Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or more_horizontal

Krystal Biotech Inc. KRYS, +5.49% shares rose Friday after the biotech drug company received Food and Drug Administration approval of a rare skin dise more_horizontal